Table 1 Baseline characteristics of 51 HER2-positive advanced breast cancer patients With T-DM1 Treatment
Variable | Number(%) |
|---|---|
Age (years) | |
  < 60 | 43(84.3) |
  ≥ 60 | 8(15.7) |
ECOG PS | |
 0 | 30(58.8) |
 1 and 2 | 21(41.2) |
Menstrual status | |
 Menopause | 39(76.5) |
 Non-menopause | 12(23.5) |
CTCAE grades | |
  ≤ 2 | 38(74.5) |
  > 2 | 13(25.5) |
Treatment lines | |
  < 2 | 32(62.7) |
  ≥ 2 | 19(37.3) |
Previous treatment | |
 Trastuzumab | 27(52.9) |
 Trastuzumab plus pertuzumab | 12(23.5) |
 Lapatinib / Pyrotinib | 2(3.9) |
 Others | 10(19.6) |
BMC status | |
 De novo | 5(9.8) |
 Recurrent | 46(90.2) |
Metastatic sites | |
 Brain | 10(19.6) |
 Bone | 25(49.0) |
 Lung | 13(25.5) |
 Liver | 27(52.9) |
 Chest wall | 12(23.5) |
 Lymph node | 22(43.1) |
HER2 status | |
 HER2(IHC2+)FISH(+) | 6(11.8) |
 HER2(IHC3+) | 45(88.2) |
HR status | |
 Positive | 19(37.3) |
 Negative | 32(62.7) |
Number of metastatic sites | |
  ≤ 2 | 9(17.6) |
  > 2 | 42(82.4) |
Prior surgery | |
 Yes | 46(90.2) |
 No | 5(9.8) |
dNLR | |
  > 1.985 | 15(29.4) |
  ≤ 1.985 | 36 (70.6) |
LDH | |
  > 244 | 21(41.2) |
  ≤ 244 | 30(58.8) |
LNI scores | |
 0 | 24(47.1) |
 1 | 17(33.3) |
 2 | 10(19.6) |
LDH changing trend | |
 Down | 16(31.4) |
 Steady | 15(29.4) |
 Up | 20(39.2) |
dNLR changing trend | |
 Down | 26(51.0) |
 Steady | 13(25.5) |
 Up | 12(23.5) |